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Tridecaptin-inspired antimicrobial peptides with
activity against multidrug-resistant Gram-negative
bacteria†
Ross D. Ballantine, a Conor E. McCallion,a Elie Nassour, b
Sima Tokajian b and Stephen A. Cochrane *a
Antimicrobial peptides are a rich source of potential antibiotic candidates. The tridecaptins, a family of lin-
ear lipo-tridecapeptides, are easily synthesized and show strong activity against Gram-negative bacteria.
However, their composition includes several expensive amino acids, such as D/L diaminobutyric acid and D-
allo-isoleucine, significantly increasing their cost of synthesis. Herein, we report a series of new tridecaptin
derivatives that are much cheaper to synthesize and retain strong activity against multidrug-resistant
Gram-negative bacteria.
Introduction
One of the most significant challenges facing our generation
is antimicrobial resistance (AMR).1–3 The human and finan-
cial cost of AMR is rising and failure to act could mean it
causes more deaths than cancer by 2050.4 The World Health
Organization has published a priority pathogens list, with the
critical pathogens being carbapenem-resistant Acinetobacter
baumannii, Pseudomonas aeruginosa and Enterobacteriaceae.5
These are all Gram-negative bacteria, which are significantly
harder to treat than Gram-positive species as their outer-
membrane blocks many antibiotics. Non-ribosomal peptides
(NRPs) are attractive lead compounds in antibiotic develop-
ment due to their large structural diversity. In recent years
many NRPs have been discovered (or re-elucidated) that kill
MDR bacteria, often through novel mechanisms of action.6,7
The tridecaptins are a family of linear NRPs that are
N-terminally acylated and composed of 13 amino acids, more
than half of which are non-proteinogenic residues (Fig. 1).8–11
They selectively kill Gram-negative bacteria by binding to the
cell-wall precursor lipid II and disrupting the inner-mem-
brane.12 This selective-binding was recently exploited to de-
velop a tridecaptin-based fluorescent probe for differential
staining of Gram-negative bacteria.13 It has also been shown
that Escherichia coli does not develop resistance to octyl-
tridecaptin A1 (Oct-TriA1) during continuous exposure over a
30 day period, highlighting its potential as an antibiotic lead
candidate.12
The tridecaptins are produced by Bacillus and
Paenibacillus species, however their production yields are low
(<5 mg L−1).8,9 In contrast, solid-phase peptide synthesis
(SPPS) can be used to prepare sizeable quantities of
tridecaptins for structure–activity relationship (SAR)
studies.14–17 A particular advantage that the tridecaptins have
over many other antimicrobial NRPs is that they are not cy-
clic. This allows them to be easily assembled by SPPS without
the need for orthogonal protecting group strategies and
solution- or solid-phase macrocyclizations. However, a poten-
tial drawback in the chemical synthesis of the tridecaptins is
the higher cost of some of the orthogonally-protected Fmoc-
amino acids required, including Fmoc-DabĲBoc), Fmoc-D-
Med. Chem. Commun.This journal is © The Royal Society of Chemistry 2019
a School of Chemistry and Chemical Engineering, David Keir Building, Queen's
University Belfast, Stranmillis Road, Belfast, BT9 5AG, UK.
E-mail: s.cochrane@qub.ac.uk
bDepartment of Natural Sciences, School of Arts and Sciences, Lebanese American
University, Byblos, Lebanon
† Electronic supplementary information (ESI) available. See DOI: 10.1039/
c9md00031c
Fig. 1 Structure of tridecaptin analogue Oct-TriA1 (1). D-Amino acids
are labelled, the N-terminal lipid tail is highlighted in yellow and some
of the most expensive non-proteinogenic amino acids are highlighted
in blue.
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DabĲBoc) and Fmoc-D-allo-Ile. If conservative substitutions
could be made at positions containing these non-
proteinogenic residues, the cost of synthesis would be signifi-
cantly lowered. A previous alanine scan showed that several
residues could be substituted with alanine in Oct-TriA1 with-
out a significant loss of activity, however positions including
D-Dab8 are vital.18 Herein we report our development of novel
linear antimicrobial peptides based on the tridecaptin scaf-
fold, that retain their activity against Gram-negative bacteria
but are significantly cheaper to synthesize.
Results and discussion
Oct-TriA1 (1) was first synthesized using automated Fmoc-
SPPS (CEM Liberty 12 peptide synthesizer) (Scheme 1). Micro-
wave assisted amino acid couplings and N-Fmoc
deprotections allow these peptides to be efficiently assembled
in reasonable overall yields (4–11%). Tridecaptin analogues
are also readily synthesized by manual SPPS at room temper-
ature, using 45 min couplings (HATU) and 3 × 1 min
deprotections. Although more time consuming, we find the
yield and crude purity of these peptides are superior to those
synthesized by automated SPPS. After synthesis, the peptide
is purified by reversed-phase (C18) high-performance liquid
chromatography (RP-HPLC) for antimicrobial testing.
Previous studies have shown that the tridecaptins have
strong activity against clinically relevant Gram-negative
strains.8,14 This includes A. baumannii and Enterobacteriaceae
such as Klebsiella pneumoniae and Enterobacter spp., however
P. aeruginosa is less susceptible. The World Health Organiza-
tion (WHO) currently lists carbapenemase-producing strains
of these Gram-negative bacteria as critical priority pathogens.
We therefore decided to synthesize a library of novel
tridecaptin analogues containing conservative substitutions
at positions 2, 7, 8 and/or 12, and evaluate their activity
against a panel of these strains (Table 1). This panel of
Gram-negative bacteria contains environmental samples iso-
lated from sewage contaminated water in Lebanon, as well
as several strains isolated from patients at clinical set-
tings. The antibiotic susceptibility of these strains varies
(see ESI†) but several of the clinical isolates are
carbapenemase-producing organisms. In particular, A.
baumannii ACM 11 and ACM 29 are extended-spectrum-β-
lactamase-producing strains resistant to many β-lactam anti-
biotics, including the penicillins amoxicillin and ticarcillin,
the carbapenems imipenem and ertapenem, and the cephalo-
sporins cefalotin and cefuroxime. These strains are also resis-
tant to several aminoglycosides and fluoroquinolones, al-
though are susceptible to colicin.
The first amino acid substitution we explored was replace-
ment of D-allo-Ile12 with D-Val, which occurs in natural TriA2
variants. Fmoc-D-Val is ∼30 times less expensive than Fmoc-
D-allo-Ile (according to Fluorochem pricing). The antimicro-
bial activity of Oct-TriA2 (2) is two- to four-fold less active
than Oct-TriA1 (1) against most strains tested. The minimum
inhibitory concentrations (MICs) of Oct-TriA1 against K.
pneumoniae and E. cloacae strains were typically 6.25 μg mL−1
but lower against carbapenemase-producing A. baumannii
strains (25 μg mL−1). These results suggest that an additional
methyl unit at position 12 has a small but positive contribu-
tion to the antimicrobial activity.
We next proceeded to replace the D-Dab and L-Dab resi-
dues, found at positions 2 and 8, and 7 respectively. Longer
chain basic amino acids, such as Lys and Orn, are signifi-
cantly cheaper than their Dab counterparts. It was previously
shown that D-Dab8 is essential for antimicrobial activity,18
and an experimentally derived model of Oct-TriA1 bound to
its cellular receptor, the peptidoglycan intermediate lipid II,
supports this observation.12 Therefore we first prepared pep-
tides in which only the amino acids at positions 2 and 7 were
substituted with Lys or Orn (D/L configuration retained). Oct-
TriA1 (2-D-Orn, 7-Orn) (3) and Oct-TriA1 (2-D-Lys, 7-Lys) (4)
have comparable antimicrobial activity but are two- to four-
fold less active than Oct-TriA1 against all of the Acinetobacter
and Enterobacteriaceae spp. tested. However, both peptides 3
and 4 have enhanced antimicrobial activity against P. pseudo-
alcaligenes. Encouraged by these results, we then proceeded
to synthesize and test variants in which D-Dab8 had also been
substituted. Oct-TriA1 (2,8-D-Orn, 7-Orn) (5) and Oct-TriA1
(2,8-D-Lys, 7-Lys) (6) also retain their Gram-negative activity,
with comparable MICs to peptides 3 and 4 against most
strains. Finally, the Lys/Orn substitutions at the 2, 7 and 8 po-
sitions were also incorporated into TriA2 analogues, yielding
Oct-TriA2 (2,8-D-Orn, 7-Orn) (7) and Oct-TriA2 (2,8-D-Lys, 7-Lys)
(8). At this stage the triple Oct-TriA2 mutant 8 showed no
antimicrobial activity at the highest concentrations tested
(100 μg mL−1). Gratifyingly, Oct-TriA2 (2,8-D-Orn, 7-Orn) (7)
showed comparable activity to Oct-TriA1 against the A.
baumannii strains and four-fold enhanced activity against P.
pseudoalcaligenes, although was two- to four-fold less active
against the K. pneumoniae strains.
Some general conclusions can be drawn from these re-
sults. Firstly, Oct-TriA1 (1) has the strongest antimicrobial
activity in the majority of cases, except against P. pseudo-
alcaligenes. Secondly, Oct-TriA2 analogues are two- to four-
fold less active than their Oct-TriA1 counterparts in most
cases. Thirdly, substitution of D-Dab8 with D-Lys is more det-
rimental to activity than substitution with D-Orn. Mechanisti-
cally, this may be related to lipid II binding by the
tridecaptins, however further in vitro studies using lipid II
are required to confirm this and are beyond the scope of the
present study. Fourthly, Oct-TriA2 (2,8-D-Orn, 7-Orn) (7) is the
Scheme 1 Automated SPPS workflow used to prepare tridecaptin
analogues 1–8. MW = microwave.
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most promising variant and although less active against
some strains, it is significantly cheaper to synthesize than
Oct-TriA1.
Having assessed the antimicrobial activity of peptides 1–8
we next proceeded to assess their haemolytic activities
(Table 2). Haemolytic activity was tested at 100 μg mL−1, as
the concentration required for haemolysis should be higher
than antimicrobial MICs. Equine erythrocytes were exposed
to peptides 1–8 and incubated for 30 min at 37 °C (Table 2).
The Oct-TriA2 analogues are significantly less haemolytic
than their Oct-TriA1 counterparts. >50% haemolysis was ob-
served for most peptides, with the exception of Oct-TriA2 (2,8-
D-Orn, 7-Orn) (7) and Oct-TriA2 (2,8-D-Lys, 7-Lys) (8). The low
haemolytic activity observed for Oct-TriA2 (2,8-D-Lys, 7-Lys) (8)
is consistent with its poor antimicrobial activity. In contrast,
Oct-TriA2 (2,8-D-Orn, 7-Orn) (7), which is one of the most po-
tent new tridecaptin analogues, has lower haemolytic activity
(39.8%) than the remaining peptides. This is promising, as it
is also significantly cheaper to synthesize than Oct-TriA1.
In summary, we have synthesized novel antimicrobial pep-
tides based on the tridecaptins, wherein the most expensive
residues are replaced with cheaper analogues. Most of these
synthetic peptides retain activity against Gram-negative bacte-
ria. In particular, Oct-TriA2 (2,8-D-Orn, 7-Orn) (7), displayed
strong activity against MDR strains (clinical and environmen-
tal isolates) of A. baumannii, K. pneumoniae and E. cloacae,
several of which are carbapenem-resistant. Peptide 7 was also
four-fold more active against P. pseudoalcaligenes than the ca-
nonical Oct-TriA1, has lower haemolytic activity and is much
cheaper to synthesize. Given the need for new antimicrobials
against carbapenem resistant Gram-negative bacteria, Oct-
TriA2 (2,8-D-Orn, 7-Orn) may prove a good compound for fur-
ther development.
Conflicts of interest
There are no conflicts to declare.
Table 1 Antimicrobial activity of tridecaptin derivatives 1–8
Strainb Isolate type Carbapenemase-producing?
Peptide MICa
1 2 3 4 5 6 7 8
A. baumannii Environmental No 12.5 25 100 50 12.5 6.25 25 >100
A. baumannii ACM 11 Clinical Yes 25 100 50 25 50 25 25 >100
A. baumannii ACM 29 Clinical Yes 25 50 50 50 50 25 50 >100
E. cloacae Clinical Yes 3.13 6.25 25 25 6.25 25 12.5 >100
K. pneumoniae Environmental No 6.25 12.5 100 50 12.5 50 50 >100
K. pneumoniae IMP 170 Clinical Yes 6.25 12.5 25 25 25 50 25 >100
K. pneumoniae IMP 177 Clinical Yes 6.25 25 25 25 25 25 12.5 >100
K. pneumoniae IMP 204 Clinical Yes 12.5 12.5 25 25 25 50 12.5 >100
K. pneumoniae IMP 216 Clinical Yes 6.25 12.5 25 25 6.25 25 12.5 >100
K. pneumoniae IMP 485 Clinical Yes 6.25 12.5 25 25 25 25 12.5 >100
P. pseudoalcaligenes Environmental No 50 50 12.5 25 50 100 6.25 >100
a MIC = minimum inhibitory concentration. Determined by microbroth dilutions assays and experiments run in duplicate. Values are shown to
three significant figures and reported in μg mL−1. b Additional strain information including antibiotic susceptibility and isolation data are
available in the ESI.
Table 2 Haemolytic activity of tridecaptin derivatives 1–8
Peptidea % haemolysisb
1 89.6
2 52.1
3 66.7
4 71.4
5 77.5
6 86.4
7 39.8
8 2.8
a All peptides were tested at 100 μg mL−1. b Experiments were run in
triplicate. Absorbance was measured at 415 nm and percent
haemolysis of the peptides were calculated relative to Triton X-100
(taken as 100%).
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